2篇
您的检索式：作者名="Liangping Luo"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Fractal description and quantitative analysis of normal brain development in infants显示文摘We examined the fractal pattern of cerebral computerized tomography images in 158 normal infants, aged 0-3 years, based on the quantitative analysis of chaotic theory. Results showed that the fractal dimension of cerebral computerized tomography images in normal infants remained stable from 1.86-1.91. The normal distribution range in the neonatal period, 1-2 months old infants, 1-2 year old infants, and of 2-3 year old infants was 1.88-1.90 (mean: 1.891 3 ± 0.006 4), 1.89-1.90 (mean: 1.892 7 ± 0.004 5), 1.86-1.90 (mean: 1.886 3 ± 0.008 5), and 1.88-1.91 (mean: 1.895 8 ± 0.008 3), respectively. The spectrum width of the multifractal spectrum (△α) in normal infants was 1.4618. These data suggest that the spectral width parameters of the multifractal spectrum and the fractal dimension criteria in normal children may be useful as a practical specific parameter for assessing the fractal mode of brain development in normal infants. | Hehong Li Liangping Luo Li Huang | 2011 | Neural Regeneration Research2011，6，34： | 0 |
| 2 | A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer显示文摘Epidermal growth factor receptor(EGFR)tyrosine kinase inhibitors(TKI),such as Erlotinib,have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer(NSCLC)patients with mutated EGFR.However,the efficacy of EGFR-TKIs in wild-type(wt)EGFR tumours has been shown to be marginal.Methods that can sensitize Erlotinib to EGFR wild-type NSCLC remain rare.Herein,we developed a multifunctional superparamagnetic nanotheranostic agent as a novel strategy to potentiate Erlotinib to EGFR-wt NSCLCs.Our results demonstrate that the nanoparticles can co-escort Erlotinib and a vascular epithermal growth factor(VEGF)inhibitor,Bevacizumab(Bev),to EGFR-wt tumours.The nanotheranostic agent exhibits remarkable effects as an inhibitor of EGFR-wt tumour growth.Moreover,Bev normalizes the tumour embedded vessels,further promoting the therapeutic efficacy of Erlotinib.In addition,the tumour engagement of the nanoparticles and the vascular normalization could be tracked by magnetic resonance imaging(MRI).Collectively,our study,for the first time,demonstrated that elaborated nanoparticles could be employed as a robust tool to potentiate Erlotinib to EGFR-wt NSCLC,paving the way for imaging-guided nanotheranostics for refractory NSCLCs expressing EGFR wild-type genes. | Duo Wang Jun Zhou Weimin Fang Cuiqing Huang Zerong Chen Meng Fan Ming-Rong Zhang Zeyu Xiao Kuan Hu Liangping Luo | 2022 | Bioactive Materials2022，7，7： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员